The Feasibility of Osimertinib Treatment on Brain Metastases in NSCLC Patients After 1st Generation EGFR-TKI Resistance: A Preliminary Study

被引：0

作者：

Zhu, L. ^{[1
]}

Zhang, S. ^{[2
]}

Xia, B. ^{[3
]}

Chen, X. ^{[4
]}

Ma, S. ^{[1
]}

机构：

[1] Nanjing Med Univ, Hangzhou Peoples Hosp 1, Dept Radiat Oncol, Hangzhou, Zhejiang, Peoples R China

[2] Nanjing Med Univ, Hangzhou Peoples Hosp 1, Ctr Translat Med, Hangzhou, Zhejiang, Peoples R China

[3] Hangzhou Canc Hosp, Dept Radiat Oncol, Hangzhou, Zhejiang, Peoples R China

[4] Hangzhou First Peoples Hosp, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China

来源：

关键词：

osimertinib; Brain metastasis; lung cancer;

D O I：

10.1016/j.jtho.2017.09.310

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1.01-046

引用

页码：S1910 / S1910

页数：1